Company Overview and News

 
KLCI gains after US equities' overnight rise

3h theedgemarkets
KUALA LUMPUR (Oct 17): The FBM KLCI gained 3.75 points or 0.22% today with Asian shares after US equities' overnight rise.
HLFBF 3867 5819 1082 BATS 4162 2836 5246

 
KLCI pares gains as sellers outpace buyers

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI pared some of its gains at midday break today, as sellers outpaced buyers at the local bourse, against the backdrop of modest gains at regional markets.
HLFBF 7113 BATS TPGVF 4162 5037 2089 9334 5199 3867 2836 HIPEF UPBMF 1082 5220 5681 7765 7066 0131 7123 TGLVY 5139 4588 0900 5819

 
KLCI pares gains as Trump threatens more tariffs on China

2018-10-15 theedgemarkets
KUALA LUMPUR (Oct 15): The FBM KLCI pared some of its gains at midday break, as regional markets remained jittery with U.S.President Donald Trump threatening to impose another round of tariffs on China.
HLFBF 5183 PECGF 1082 7113 5681 TPGVF 7006 5168 5014 9334 6033 5199 TGLVY 5238 4588 PNADF MYPRY HIPEF PNAGF HRGHY

 
KLCI rises 0.24% as blue chips lift

2018-10-15 theedgemarkets
KUALA LUMPUR (Oct 15): The FBM KLCI rose 0.24% at mid-morning today, defending its level above the 1,730-point level, lifted by gains at select blue chips.
HLFBF 7293 BRDBF MLYNF 7113 TPGVF 2089 5199 5210 3026 2836 HIPEF GEBHF HRGHY 5183 MLYBY PECGF UPBMF 1082 5681 5168 TGLVY 5436 5238 1155 0047

 
KLCI up 0.79% in technical rebound, Maybank and TNB lift

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): The FBM KLCI rose 0.79% in a technical rebound at the midday break today, snapping its seven-day losing streak, lifted by index heavyweights including Malayan Banking Bhd (Maybank) and Tenaga Nasional Bhd (TNB).
HLFBF MLYBY MLYNF 7036 1082 7006 5135 6033 5199 CIMDF 1155 KLKBY 1023 2445 PNADF 5347 TNABY 6888 0006 5819 AXXTF TNABF HIPEF PNAGF

 
KLCI starts lower in line with frail regional markets

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): The FBM KLCI fell for the eighth day running this morning, amid frail regional sentiment.
HLFBF 3026 PBLOF 3867 5819 1082 1295 BSMAF 3034 7022 GBTKF 1818

 
KLCI pares loss as region remains weaker

2018-10-09 theedgemarkets
KUALA LUMPUR (Oct 9): The FBM KLCI pared some of its losses at the midday break today, against a backdrop of weaker regional markets.
HLFBF UPBMF 7036 1082 5010 BATS 4162 2291 7765 3794 2089 5256 9334 5199 KLKBY 5139 2445 0900 8613 6888 AXXTF 5827 HIPEF 3719

 
KLCI pares loss, remains in red tracking regional markets

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): The FBM KLCI pared some of its loss at mid-morning today, but remained in the negative zone in line with its key regional peers.
HLFBF SPMXF UPBMF 7036 1082 7113 TPGVF BATS 4162 7087 2089 9334 7123 TGLVY SPMXY 5225 3026 3301 0026 1899 Q0F IHHHF GEBHF

 
FBM KLCI down 0.72% on profit taking as US bond yield rise hits world markets

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): The FBM KLCI closed down 12.96 points or 0.72% today after local institutional investors took profit and as higher US government bond or Treasury yields at above 3% hit Asian financial markets.
HLFBF PNADF 6888 1082 5681 AXXTF PNAGF 6033

 
KLCI remains in the red, tracks regional slump

2018-10-04 theedgemarkets
KUALA LUMPUR (Oct 4): The FBM KLCI retreated at the midday break, in line with slump at most regional markets.
HLFBF 5183 PECGF 1082 BATS 4162 7765 5014 9334 7123 5199 4588 3026 0026 5219 MYPRY HIPEF

 
KLCI edges up, gains seen capped

2018-10-04 theedgemarkets
KUALA LUMPUR (Oct 4): The FBM KLCI edged up in early trade, tracking its regional peers but any gain at the local bourse is seen limited.
HLFBF 5139 PNADF 0900 1082 BATS 4162 PNAGF 6033

 
KLCI trends higher in cautious trading

2018-10-02 thestar.com.my
KUALA LUMPUR: Continuous buying by funds and gains on heavyweights helped propel the benchmark FBM KLCI index higher on Tuesday. The FBM KLCI added 5.69 points, or 0.32%, to close at 1,798.15 on strong interest in Genting Group stocks as well banking stocks. The market traded within a range of 5.53 points between an intra-day high of 1,797.20 and a low of 1,791.67 during the session. Market breadth was negative with 554 gainers, 376 losers and 365 counters unchanged on the Bursa Malaysia.
GMALY HLFBF 4863 4715 GMALF 1082 MYTEF BSMAF 1818

 
KLCI stays shy of 1,800 as regional markets retreat

2018-10-02 theedgemarkets
KUALA LUMPUR (Oct 2): The FBM KLCI was hard pressed to find a firm footing in the morning session and remained below the crucial 1,800-point level at the midday break, as regional markets retreated.
HLFBF BRDBF UPBMF 1082 5168 2089 5256 5255 9334 5199 5210 4634 5139 4456 3026 0900 0026 7108 2836 HIPEF GEBHF HRGHY

 
FBM KLCI down on profit taking ahead of weekend

2018-09-28 theedgemarkets
KUALA LUMPUR (Sept 28): The FBM KLCI closed down 5.49 points or 0.31% on profit taking and after fund managers realigned their portfolios following the US interest rate hike.
HLFBF 6888 1082 5681 AXXTF

 
KLCI slips below 1,800 level as sellers outpace buyers

2018-09-27 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI slipped back to below the 1,800-point level at midday break today, as sellers overtook buyers at the local bourse.
HLFBF 7113 7158 BATS TPGVF 4162 2089 5199 5347 7668 TNABY AXXTF 2836 HIPEF 1929 UPBMF 1082 6399 1163 5202 8311 2593 TGLVY 5139 0900 6888 TNABF 3719

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...